Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
暂无分享,去创建一个
E. Scarpi | B. Mellado | V. Conteduca | U. de Giorgi | G. Schepisi | G. Gurioli | D. Olmos | G. Attard | E. Gonzalez-Billalabeitia | C. Lolli | N. Romero-Laorden | E. Castro | D. Wetterskog | R. Lozano | A. Jayaram | C. Casadei | M. Marín-Aguilera | A. Wingate | N. Brighi | I. Aragón
[1] V. Conteduca,et al. Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. , 2021, European urology oncology.
[2] V. Conteduca,et al. New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer , 2021, Cells.
[3] H. Scher,et al. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. , 2020, European urology.
[4] A. Wyatt,et al. Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. , 2019, JCO precision oncology.
[5] E. Scarpi,et al. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. , 2019, European journal of cancer.
[6] E. Scarpi,et al. Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. , 2019, JCO precision oncology.
[7] A. Zoubeidi,et al. Biological Evolution of Castration-resistant Prostate Cancer. , 2019, European urology focus.
[8] E. Scarpi,et al. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer , 2019, European urology.
[9] E. Gallardo,et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Wyatt,et al. Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA). , 2018 .
[11] D. Amadori,et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Matti Nykter,et al. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.
[13] Oliver Sartor,et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Scarpi,et al. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer , 2016, Oncotarget.
[15] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[16] Delila Gasi Tandefelt,et al. Plasma AR and abiraterone-resistant prostate cancer , 2015, Science Translational Medicine.
[17] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[18] E. Wiemer,et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. , 2015, European urology.
[19] D. Amadori,et al. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone , 2015, British Journal of Cancer.
[20] E. Wiemer,et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. , 2013, European journal of cancer.
[21] H. Joensuu,et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. , 2013, The Lancet. Oncology.
[22] H. Joensuu,et al. Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. , 2012, Anticancer research.
[23] N. Bander,et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. , 2011, Cancer research.
[24] D. Qian,et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. , 2010, Cancer research.
[25] Yuzhuo Wang,et al. Experimental Therapeutics , Molecular Targets , and Chemical Biology Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer , 2009 .
[26] S. Fosså,et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. , 2007, European urology.
[27] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[28] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[29] T. Beer,et al. Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients Aged ≥ 70 Years Compared with Patients Aged < 70 Years , 2003 .